JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Ocular Therapeutix Inc

Затворен

СекторЗдравеопазване

11.92 -3.09

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

10.53

Максимум

12.31

Ключови измерители

By Trading Economics

Приходи

-16M

-64M

Продажби

-6.4M

11M

Марж на печалбата

-602.342

Служители

274

EBITDA

-20M

-64M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+45.75% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

643M

2B

Предишно отваряне

15.01

Предишно затваряне

11.92

Настроения в новините

By Acuity

38%

62%

137 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Ocular Therapeutix Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2025 г., 23:11 ч. UTC

Печалби

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5.08.2025 г., 22:45 ч. UTC

Печалби

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5.08.2025 г., 22:39 ч. UTC

Печалби

Great-West Lifeco Logs Lower 2Q Profit

5.08.2025 г., 21:32 ч. UTC

Печалби

Coupang Posts Higher 2Q Sales Due to Customer Growth

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5.08.2025 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5.08.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5.08.2025 г., 23:19 ч. UTC

Пазарно говорене

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5.08.2025 г., 23:03 ч. UTC

Пазарно говорене
Печалби

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5.08.2025 г., 22:22 ч. UTC

Печалби

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5.08.2025 г., 22:21 ч. UTC

Печалби

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5.08.2025 г., 22:20 ч. UTC

Печалби

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5.08.2025 г., 22:18 ч. UTC

Печалби

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5.08.2025 г., 22:17 ч. UTC

Печалби

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5.08.2025 г., 22:17 ч. UTC

Печалби

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5.08.2025 г., 22:16 ч. UTC

Печалби

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5.08.2025 г., 22:16 ч. UTC

Печалби

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5.08.2025 г., 22:15 ч. UTC

Печалби

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5.08.2025 г., 22:13 ч. UTC

Печалби

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5.08.2025 г., 22:13 ч. UTC

Печалби

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5.08.2025 г., 22:12 ч. UTC

Печалби

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5.08.2025 г., 22:12 ч. UTC

Печалби

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5.08.2025 г., 21:58 ч. UTC

Печалби

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5.08.2025 г., 21:30 ч. UTC

Печалби

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5.08.2025 г., 21:26 ч. UTC

Печалби

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5.08.2025 г., 21:23 ч. UTC

Печалби

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5.08.2025 г., 21:17 ч. UTC

Печалби

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Сравнение с други в отрасъла

Ценова промяна

Ocular Therapeutix Inc Прогноза

Ценова цел

By TipRanks

45.75% нагоре

12-месечна прогноза

Среден 18 USD  45.75%

Висок 22 USD

Нисък 14 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocular Therapeutix Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

8

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

6.97 / 7.62Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

137 / 374 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.